BR0010344A - Métodos para examinar uma pluralidade de compostos para examinar compostos quanto à atividade de melhora cognitiva, para prover uma preparação farmacêutica a pacientes, para examinar uma pluralidade de compostos para a atividade de melhora de cognição, para examinar compostos quanto à atividade hipnótica, para examinar compostos tendo atividade ansiolìtica, para examinar compostos quanto à atividade antidepressiva e para prover compostos farmacêuticos a pacientes - Google Patents
Métodos para examinar uma pluralidade de compostos para examinar compostos quanto à atividade de melhora cognitiva, para prover uma preparação farmacêutica a pacientes, para examinar uma pluralidade de compostos para a atividade de melhora de cognição, para examinar compostos quanto à atividade hipnótica, para examinar compostos tendo atividade ansiolìtica, para examinar compostos quanto à atividade antidepressiva e para prover compostos farmacêuticos a pacientesInfo
- Publication number
- BR0010344A BR0010344A BR0010344-6A BR0010344A BR0010344A BR 0010344 A BR0010344 A BR 0010344A BR 0010344 A BR0010344 A BR 0010344A BR 0010344 A BR0010344 A BR 0010344A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- examining
- activity
- patients
- examine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 12
- 230000037411 cognitive enhancing Effects 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000001430 anti-depressive effect Effects 0.000 title abstract 2
- 239000000935 antidepressant agent Substances 0.000 title abstract 2
- 229940005513 antidepressants Drugs 0.000 title abstract 2
- 230000000949 anxiolytic effect Effects 0.000 title abstract 2
- 230000000147 hypnotic effect Effects 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 102000027484 GABAA receptors Human genes 0.000 abstract 1
- 108091008681 GABAA receptors Proteins 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9426—GABA, i.e. gamma-amino-butyrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"MéTODOS PARA EXAMINAR UMA PLURALIDADE DE COMPOSTOS PARA EXAMINAR COMPOSTOS QUANTO à ATIVIDADE DE MELHORA COGNITIVA, PARA PROVER UMA PREPARAçãO FARMACêUTICA A PACIENTES, PARA EXAMINAR UMA PLURALIDADE DE COMPOSTOS PARA A ATIVIDADE DE MELHORA DE COGNIçãO, PARA EXAMINAR COMPOSTOS QUANTO à ATIVIDADE HIPNóTICA, PARA EXAMINAR COMPOSTOS TENDO ATIVIDADE ANSIOLìTICA, PARA EXAMINAR COMPOSTOS QUANTO à ATIVIDADE ANTIDEPRESSIVA E PARA PROVER COMPOSTOS FARMACêUTICOS A PACIENTES". São providos métodos, que são úteis no exame de compostos quanto a propriedades de aumento da cognição, propriedades ansiolíticas, propriedades hipnóticas, ou propriedades antidepressivas. Estes métodos envolvem a determinação da eficácia in vitro e de EC~ 50~ dos compostos em séries definidas de receptores do subtipo GABA~ A~ compostos de variantes específicas de subunidades <244>, <225>, e y, de modo a desenvolver um perfil de atividade para cada composto. Opcionalmente, as atividades de ligação dos compostos em receptores GABA~ A~ são também determinadas. Como um estágio adicional, os efeitos in vivo dos compostos podem ser testados em modelos animais.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13319599P | 1999-05-07 | 1999-05-07 | |
| US13319199P | 1999-05-07 | 1999-05-07 | |
| US13315599P | 1999-05-07 | 1999-05-07 | |
| US13315499P | 1999-05-07 | 1999-05-07 | |
| PCT/US2000/012306 WO2000068691A1 (en) | 1999-05-07 | 2000-05-05 | Methods for screening gaba-modulatory compounds for specified pharmacological activities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0010344A true BR0010344A (pt) | 2002-02-19 |
Family
ID=27495014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0010344-6A BR0010344A (pt) | 1999-05-07 | 2000-05-05 | Métodos para examinar uma pluralidade de compostos para examinar compostos quanto à atividade de melhora cognitiva, para prover uma preparação farmacêutica a pacientes, para examinar uma pluralidade de compostos para a atividade de melhora de cognição, para examinar compostos quanto à atividade hipnótica, para examinar compostos tendo atividade ansiolìtica, para examinar compostos quanto à atividade antidepressiva e para prover compostos farmacêuticos a pacientes |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1177445B1 (pt) |
| JP (1) | JP2002544487A (pt) |
| AT (1) | ATE366934T1 (pt) |
| AU (1) | AU4703200A (pt) |
| BR (1) | BR0010344A (pt) |
| CA (1) | CA2371219A1 (pt) |
| DE (1) | DE60035498T2 (pt) |
| DK (1) | DK1177445T3 (pt) |
| ES (1) | ES2290031T3 (pt) |
| MX (1) | MXPA01011353A (pt) |
| PT (1) | PT1177445E (pt) |
| WO (1) | WO2000068691A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0113697A (pt) | 2000-09-06 | 2003-07-22 | Neurogen Corp | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou sal, embalagem e métodos para, para alterar a atividade transdutora de sinal dos receptores de gabaa, para tratar ansiedade, depressão, um distúrbio do sono, ou demência de alzheimer, para demonstrar a presença dos receptores de gabaa em células ou amostras de tecido e para preparar um composto |
| BR0115874A (pt) * | 2000-12-04 | 2003-10-28 | Pfizer Prod Inc | Sìntese de pirrole-amidas |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5597920A (en) * | 1992-04-30 | 1997-01-28 | Neurogen Corporation | Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes |
| GB9503601D0 (en) * | 1995-02-23 | 1995-04-12 | Merck Sharp & Dohme | Method of treatment and method of manufacture of medicament |
| ATE223576T1 (de) * | 1996-10-25 | 2002-09-15 | Neurosearch As | Methode zur identifizierung von verbindungen mit anxiolytischem potential |
-
2000
- 2000-05-05 AT AT00928860T patent/ATE366934T1/de not_active IP Right Cessation
- 2000-05-05 MX MXPA01011353A patent/MXPA01011353A/es active IP Right Grant
- 2000-05-05 AU AU47032/00A patent/AU4703200A/en not_active Abandoned
- 2000-05-05 JP JP2000616424A patent/JP2002544487A/ja active Pending
- 2000-05-05 DE DE60035498T patent/DE60035498T2/de not_active Expired - Fee Related
- 2000-05-05 CA CA002371219A patent/CA2371219A1/en not_active Abandoned
- 2000-05-05 EP EP00928860A patent/EP1177445B1/en not_active Expired - Lifetime
- 2000-05-05 WO PCT/US2000/012306 patent/WO2000068691A1/en not_active Ceased
- 2000-05-05 PT PT00928860T patent/PT1177445E/pt unknown
- 2000-05-05 DK DK00928860T patent/DK1177445T3/da active
- 2000-05-05 BR BR0010344-6A patent/BR0010344A/pt not_active Application Discontinuation
- 2000-05-05 ES ES00928860T patent/ES2290031T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE60035498T2 (de) | 2008-03-13 |
| WO2000068691A1 (en) | 2000-11-16 |
| DE60035498D1 (de) | 2007-08-23 |
| ES2290031T3 (es) | 2008-02-16 |
| EP1177445B1 (en) | 2007-07-11 |
| PT1177445E (pt) | 2007-10-19 |
| AU4703200A (en) | 2000-11-21 |
| EP1177445A1 (en) | 2002-02-06 |
| ATE366934T1 (de) | 2007-08-15 |
| DK1177445T3 (da) | 2007-11-05 |
| JP2002544487A (ja) | 2002-12-24 |
| CA2371219A1 (en) | 2000-11-16 |
| MXPA01011353A (es) | 2002-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Choi et al. | Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study | |
| Horwath et al. | Fiber type-specific hypertrophy and increased capillarization in skeletal muscle following testosterone administration in young women | |
| Abramowitz et al. | Skeletal muscle fibrosis is associated with decreased muscle inflammation and weakness in patients with chronic kidney disease | |
| McKendry et al. | Superior aerobic capacity and indices of skeletal muscle morphology in chronically trained master endurance athletes compared with untrained older adults | |
| Campisi et al. | Acute psychosocial stress differentially influences salivary endocrine and immune measures in undergraduate students | |
| BRPI0518307A2 (pt) | mÉtodo e composiÇço de matÉria para tratar um indivÍduo tendo um cÂncer, kit, composiÇço farmacÊutica, mÉtodo para impregnar ou carregar um dispositivo implantÁvel de liberaÇço de droga, dispositivo implantÁvel de liberaÇço de droga, mÉtodo para avaliar a resposta de um indivÍduo tendo cÂncer a um tratamento usando um agonista de tlr3 ou selecionar um indivÍduo tendo um cÂncer que responde a um tratamento usando um agonista de tlr3, complexo, mÉtodo para determinar se um composto de teste É étil para o tratamento de cÂncer, e, uso de um agonista de tlr3 | |
| CY1121162T1 (el) | M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου | |
| ECSP099225A (es) | Compuestos antagonistas del receptor de glucagón, composiciones que contienen dichos compuestos y procedimientos de uso | |
| CY1113159T1 (el) | Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις | |
| BRPI0511695A (pt) | agonistas de receptor (beta)2 adrenérgico diamina | |
| BRPI0816597A2 (pt) | "composto, composição farmacêutica, combinação, uso de um composto, método para tratar um indivíduo aflifido com uma consição patológica ou doença e método de modulação de uma atividade um receptor b2 adrenérgico" | |
| BRPI0413563A (pt) | compostos e composições como inibidores de atividade do receptor de quìnase de tirosina | |
| UY28572A1 (es) | Compuestos novedosos | |
| Bechard et al. | Toe‐out, lateral trunk lean, and pelvic obliquity during prolonged walking in patients with medial compartment knee osteoarthritis and healthy controls | |
| KR100971305B9 (ko) | 신장 질환용 진단 표지로서의 호중구 젤라티나제 결합리포칼린 의 측정 | |
| Rufino et al. | Expression and function of K (ATP) channels in normal and osteoarthritic human chondrocytes: possible role in glucose sensing | |
| RU2010101416A (ru) | Профилактическое/лекарственное средство от рака | |
| Zogby et al. | Skeletal muscle fiber‐type specific succinate dehydrogenase activity in cerebral palsy | |
| ES2531368T3 (es) | Métodos y kits para diagnosticar tumorigenicidad y determinar resistencia a los efectos antineoplásicos de la terapia antiestrógeno | |
| BRPI0414643A (pt) | composto, composições farmacêuticas, e, uso de um composto | |
| Cadet et al. | Improving bone density at the rotator cuff footprint increases supraspinatus tendon failure stress in a rat model | |
| CO5170446A1 (es) | Estuche de ensayo para el diagnostico de encefalopaatias espongiformes transmisibles | |
| BRPI0409730A (pt) | tratamento da incontinência | |
| BR112022025238A2 (pt) | Compostos heterocíclicos e agentes de imageamento para formar imagem da proteína huntingtina | |
| FR2892874B1 (fr) | Dispositif de test d'un convertisseur analogique-numerique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 E 24 DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |